American journal of clinical pathology最新文献

{"title":"The impact of gastric Helicobacter pylori infection on duodenal mucosa: New evidence on the alteration of intraepithelial lymphocytes.","authors":"Fatih Yilmaz, Kadri Atay, Gül Çirkin, Erkan Sanmak","doi":"10.1093/ajcp/aqaf071","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf071","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to elucidate the effect of gastric Helicobacter pylori (HP) colonization on the duodenal mucosa, focusing on intraepithelial lymphocyte (IEL) numbers and localizations.</p><p><strong>Methods: </strong>The paired gastric and duodenal tissues from 132 patients with celiac disease (CD) and 190 individuals without CD were examined. Gastric HP status (presence and intensity) was compared with IEL counts per 100 enterocytes (IEL/100), localizations (basal-apical), and endoscopic, serologic, and clinicopathologic parameters.</p><p><strong>Results: </strong>H pylori was detected in 176 (54.7%) gastric tissues, and its presence did not significantly change the duodenal IEL/100 counts in either CD (P = .121) or non-CD (P = .400) cases. It was seen in older individuals (P = .003), and age was also associated with HP intensity (P = .027). In non-CD cases, duodenal intraepithelial lymphocytosis (DIL) in HP-positive and HP-negative samples was 37 (33.9%) and 31 (38.3%), respectively (P = .538). Although a slight increase was observed with sparse HP colonization (+), intense colonization (+++) was significantly associated with less scalloping (P = .037), lower IEL/100 (P = .003), and antiendomysial antibody IgA (P = .048). A similar pattern was also observed in tissue transglutaminase IgA titers (P = .053).</p><p><strong>Conclusions: </strong>Considering the effect of gastric HP on duodenal IELs, endoscopic and serologic parameters, depending on its intensity, will provide a more accurate estimation in cases where the cause of DIL is investigated.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing a comprehensive artificial intelligence lifecycle framework for laboratory medicine and pathology: A series introduction.","authors":"Christopher A Garcia, Katelyn A Reed, Eric Lantz, Patrick Day, Mark D Zarella, Steven N Hart, Eric Will, John G Skiffington, Melinda Rice, Debra A Novak, David S McClintock","doi":"10.1093/ajcp/aqaf069","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf069","url":null,"abstract":"<p><strong>Objective: </strong>Despite exponential growth in artificial intelligence (AI) research for laboratory medicine and pathology, a significant gap exists between model development and clinical AI implementation. This article introduces a structured framework, the Clinical AI Readiness Evaluator (CARE), to bridge this gap and support the responsible adoption of AI in clinical laboratory settings.</p><p><strong>Methods: </strong>Building upon the Machine Learning Technology Readiness Levels framework, we developed CARE specifically for the clinical laboratory environment by incorporating health care-specific requirements, regulatory considerations, and workflow integration needs. This framework was iteratively refined through practical application across diverse AI use cases within laboratory medicine and pathology.</p><p><strong>Results: </strong>The CARE framework provides a systematic approach to AI development and implementation through 8 component workstreams: clinical use case, data, data pipeline, code, clinical user experience, clinical technology infrastructure, clinical orchestration, and regulatory compliance. Unlike generic AI frameworks, CARE distinguishes itself by emphasizing both health care and laboratory workflow integration, regulatory requirements, ethical considerations, and comprehensive validation for clinical contexts. The framework accommodates both internally developed models and commercial AI solutions, providing clear guidance through technology readiness levels and structured review processes.</p><p><strong>Conclusions: </strong>The CARE framework addresses the unique challenges of implementing AI in laboratory medicine and pathology by providing a comprehensive roadmap from initial concepts through clinical deployment and maintenance. This article, the first in a series of 4, establishes the foundational AI lifecycle framework, while subsequent articles will explore data documentation, ethical AI considerations, and governance structures. By adopting this structured approach, laboratories can responsibly harness AI's potential to enhance diagnostic accuracy and operational efficiencies and, ultimately, improve patient care.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-slide imaging for multidisciplinary tumor boards: Reshaping a lymphoma conference at a large academic medical center.","authors":"Brian Vadasz, Hamza Tariq","doi":"10.1093/ajcp/aqaf072","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf072","url":null,"abstract":"<p><strong>Objective: </strong>Pathology presentations constitute the core of multidisciplinary tumor board (MTB) meetings and play a vital role in patient management in the era of personalized oncology. In most academic medical institutions, these presentations are delivered by pathology trainees using PowerPoint (PPT) slides, which can be time-consuming to prepare and challenging to execute. Whole-slide imaging (WSI) presents a valuable opportunity to create more efficient MTB workflows and enhance participant satisfaction.</p><p><strong>Methods: </strong>We share our experience of converting our weekly lymphoma MTB at Northwestern Memorial Hospital from PPT to WSI. We created surveys to evaluate the overall satisfaction of lymphoma MTB participants and hematopathology fellows using WSI vs PPT.</p><p><strong>Results: </strong>A total of 14 MTB participants were surveyed who favored WSI over static photomicrographs/PPT by a wide margin (85.7% vs 14.3%), citing advantages such as improved visualization of tissue architecture and the quality and adequacy of the biopsy, ability to see a greater proportion of the tissue, ease of immunohistochemistry interpretation, and the advantage of having their unanticipated questions answered in real time. Additionally, 8 hematopathology fellows were surveyed, who also favored WSI (87.5% vs 12.5%), citing the improved time efficiency and educational experience, better preparedness to tackle clinicians' questions in real time, improved command over cases, and the added advantage of having a digital repository for educational use.</p><p><strong>Conclusions: </strong>Our findings show that employing WSI for pathology presentations in MTBs boosts participant satisfaction, decreases preparation time, improves workflow efficiency, increases educational value, and improves the well-being of pathology trainees.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epstein-Barr virus-positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop.","authors":"Leticia Quintanilla-Martinez, Shaoying Li, Amy Chadburn","doi":"10.1093/ajcp/aqaf020","DOIUrl":"10.1093/ajcp/aqaf020","url":null,"abstract":"<p><strong>Objectives: </strong>To summarize the conclusions of the 2023 Society for Hematopathology/European Association for Haematopathology workshop regarding Epstein-Barr virus (EBV)-positive T- and natural killer (NK)-cell lymphoproliferative disorders (LPDs).</p><p><strong>Methods: </strong>There were 38 cases submitted to session 3 of the workshop.</p><p><strong>Results: </strong>Cases included extranodal NK/T-cell lymphoma (ENKTCL), nasal type (n = 16), EBV+ T- and NK-cell LPDs in children (n = 12), primary nodal EBV+ T- and NK-cell lymphoma (n = 5), and other EBV+ T- and NK-cell LPDs (n = 5). The ENKTCL cases highlighted some unusual features like indolent behavior, small cell morphology, and T-cell phenotype, including cases with CD4 and CD30 expression. The differential diagnosis of ENKTCL was illustrated by 4 cases with other primary cutaneous lymphomas. The difficulty in the diagnosis of systemic chronic active EBV disease, its complications, and the sometimes elusive boundaries among the EBV+ LPDs in children are also discussed. The submitted cases also unveiled cases of EBV+ γδ T-cell leukemia/lymphoma not recognized under current classifications and cases of EBV+ CD8+ cytotoxic lymphomas associated with treatment for B-cell lymphomas. The need to have a low threshold to investigate the presence of EBV is highlighted.</p><p><strong>Conclusions: </strong>The diagnosis of EBV+ T- and NK-cell LPDs is complex and requires a multiparameter approach incorporating clinical information and morphologic and molecular features.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"46-64"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noncutaneous cytotoxic T-cell lymphomas: Recent advances and emerging concepts: A report of the 2023 Society of Hematopathology/European Association for Haematopathology T-cell lymphoma workshop.","authors":"Sanam Loghavi, L Jeffrey Medeiros","doi":"10.1093/ajcp/aqaf016","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf016","url":null,"abstract":"<p><strong>Objectives: </strong>To review and discuss cases submitted to the 2023 Society of Hematopathology/European Association for Haematopathology workshop session entitled \"Non-cutaneous Cytotoxic T-cell Lymphomas Including Hepatosplenic T-cell Lymphoma and Intestinal T-cell Lymphomas.</p><p><strong>Methods: </strong>A total of 45 cases were submitted by various contributors. These cases included clinicopathologic, immunophenotypic and molecular data.</p><p><strong>Results: </strong>Cases submitted included 12 hepatosplenic T-cell lymphoma (HSTCL) and 22 intestinal T or NK cell lymphomas or lymphoproliferative disorders (LPD) of various types. The latter group included 12 monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), 4 indolent NK-cell LPD of the gastrointestinal (GI) tract, 3 indolent (clonal) T-cell lymphoma of the GI tract, 1 refractory celiac disease type 2, 1 enteropathy-associated T-cell lymphoma and 1 intestinal T-cell lymphoma not otherwise specified. There were also 11 miscellaneous cases that did not readily fit into well known diagnostic categories but raised questions about diagnostic criteria or biology or which elucidated aspects of differential diagnosis.</p><p><strong>Conclusions: </strong>The cases submitted were instructive and helped to further characterize and, in some cases, expand these entities. We suggest that HSTCL is a disease with well recognized clinicopathologic features and genetic features. Patients were older than is reflected in the literature. The cases of MEITL in this workshop came mostly from western and/or in industrialized nations. SETD2 mutation or loss of H3K36me3 by immunohistochemistry as a surrogate for this mutation is very common and a helpful diagnostic tool in MEITL. A surprising finding was that some patients with NK-cell LPD of the GI tract exhibited aggressive clinical features including 1 patient who had disease dissemination to the lungs and bile duct.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"36-45"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous T-cell lymphomas other than mycosis fungoides: Unusual clinical and pathologic presentations: a report of the 2023 SH-EA4HP Lymphoma Workshop (session 4).","authors":"Joan Guitart, Roberto N Miranda","doi":"10.1093/ajcp/aqaf030","DOIUrl":"10.1093/ajcp/aqaf030","url":null,"abstract":"<p><p>Thirty-two cases of cutaneous T-cell lymphoma other than mycosis fungoides were discussed at the 2023 Society of Hematopathology-European Association for Haematopathology Workshop, held November 9-11, 2023, in Houston, Texas. This session focused on diagnostically challenging rare clinical and pathologic presentations with an overrepresentation of cytotoxic cutaneous lymphomas. The variety of challenging cases reviewed in the session highlights the shortfalls of our present cutaneous lymphoma classification and provides a rich learning experience for future classification updates. Many of the cases reviewed revealed a broad and often surprising mutational profile that will contribute to more precise and molecularly relevant future classification as well as (possibly) therapeutic approaches.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"126-141"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood- and bone marrow-based mature T-cell and natural killer cell leukemias and lymphomas: a summary in the series of the 2023 SH/EAHP Workshop.","authors":"Wei Wang, Magdalena Czader, Sa A Wang","doi":"10.1093/ajcp/aqaf009","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf009","url":null,"abstract":"<p><p>This session included 51 cases submitted to the workshop \"Progress in T- and NK-cell Lymphomas and Leukemias\" by the Society for Hematopathology and European Association for Haematopathology under \"Blood/Bone Marrow-Based Mature T- and NK-Cell Leukemias/Lymphomas\" or \"T/NK-cell neoplasms with a Leukemic Presentation.\" Entities encompassed T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia (LGLL), natural killer (NK)-LGLL/chronic lymphoproliferative disorder of NK cells, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, and their mimics. Submitted cases illustrated classic and variant morphology, immunophenotype, and clinical features; the overlaps with reactive T-cell /NK-cell lymphoproliferations; and challenges in differentiating these entities from other T-cell/NK-cell neoplasms with a leukemic presentation. The cases were assessed using a multidisciplinary approach that included advancements in molecular genetics with their potential impact on clinical practice. We used the most recent classifications and summarized the key points relevant to diagnoses and differential diagnoses of respective entities.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"7-25"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.","authors":"Olga K Weinberg, Carlos E Bueso-Ramos, Rashmi Kanagal-Shamanna","doi":"10.1093/ajcp/aqaf015","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf015","url":null,"abstract":"<p><strong>Objectives: </strong>The 2023 Society for Hematopathology/European Association for Hematopathology Workshop addressed advancements in the diagnosis and classification of T- and natural killer (NK)-cell lymphomas/leukemias.</p><p><strong>Methods: </strong>Session 8 of the workshop collected a diverse set of 38 cases of immature T- and NK-cell lymphoma/leukemias, as well as acute leukemia of ambiguous lineage (ALAL) and other miscellaneous cases, including indolent T-lymphoblastic proliferations.</p><p><strong>Results: </strong>Twenty patients with T-lymphoblastic leukemia/lymphoma (T-LBL/L) and 3 patients with early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) presented at a median age of 21.5 years. Male sex was predominant (70% of all cases), with 40% having a mediastinal mass. Cases (60%) were negative for both CD34 and TdT. In addition, 7 ALAL and 3 mixed phenotype acute leukemia, T/myeloid subtypes were submitted with a median presenting age of 16 (range, 11-56) years, and most patients (67%) frequently showed adenopathy or splenomegaly. A single case of NK acute lymphoblastic leukemia was also submitted.</p><p><strong>Conclusions: </strong>This session highlighted unusual T-LBL/L cases with expression of cytotoxic markers, γ/δ phenotype, a more mature immunophenotype, and ALAL that are challenging to classify. Among T-ALL cases, interesting relapse changes were identified, with 1 patient developing a mature NK-cell phenotype. Patients with ALAL presented in an unusual setting of prior therapy or a germline mutation.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"26-35"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaplastic large cell lymphoma: unusual clinical and pathologic findings: A report of the 2023 SH-EA4HP Lymphoma Workshop.","authors":"Jie Xu, Eric D Hsi, Roberto N Miranda, Mario L Marques-Piubelli, L Jeffrey Medeiros, Andrew L Feldman","doi":"10.1093/ajcp/aqaf029","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf029","url":null,"abstract":"<p><p>Anaplastic large cell lymphoma (ALCL) cases were discussed at the 2023 Society of Hematopathology/European Association for Haematopathology workshop held on November 9-11, 2023, in Houston, Texas. This session focused on the clinical and pathologic spectrum of 3 types of ALCL: anaplastic lymphoma kinase (ALK)-positive, ALK-negative, and breast implant associated (BIA). Cases of primary cutaneous ALCL were excluded because they were included in another session. Although the diagnosis of ALCL is often straightforward, the 42 submitted cases encompassed unusual clinical presentations, morphologic variants, and atypical immunophenotypes, exemplifying potential difficulties and challenges in establishing the diagnosis of ALCL. Distinguishing ALCL from CD30-positive peripheral T-cell lymphoma, not otherwise specified, or classic Hodgkin lymphoma was discussed. In patients with a previous history of mycosis fungoides and other T-cell lymphoma/leukemia, the differential diagnosis of a CD30-positive T-cell lymphoma mimicking ALCL (mycosis fungoides transformation vs de novo ALCL) was also discussed. In patients with suspected BIA-ALCL, it is critical to properly handle the periprosthetic fluid when the disease first presents and the capsule at the time of initial capsulectomy to make a correct diagnosis and pathologic staging because a missed diagnosis may lead to disease progression. Comprehensive immunohistochemical analysis; fluorescence in situ hybridization for DUSP22, TP63, or JAK2 rearrangement; assessment of clonality of the T-cell receptor and immunoglobulin genes; and sequencing for mutations were performed as part of the workup of the submitted cases, particularly on ALK-negative ALCL cases, emphasizing the importance of ancillary testing in establishing the diagnosis.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"110-125"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomics of T-lymphoblastic leukemia/lymphoma: 2023 SH/EAHP workshop proceedings.","authors":"Rashmi Kanagal-Shamanna, Olga K Weinberg, Carlos E Bueso-Ramos","doi":"10.1093/ajcp/aqaf035","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf035","url":null,"abstract":"<p><strong>Objectives: </strong>Recent molecular characterization of T‑lymphoblastic leukemia/lymphoma (T-ALL/LBL) has deepened our understanding of the pathogenesis and created a strong foundation for novel therapeutic strategies. Consequently, both the fifth edition of the World Health Organization and the International Consensus Classification systems for T-ALL/LBL have identified genomic subtypes, some as provisional entities. However, due to the challenges encountered in uncovering these alterations, molecular testing modalities and algorithms in clinical laboratory algorithms remain inconsistent or incomplete.</p><p><strong>Methods: </strong>Cases from Session 8 of the 2023 Workshop of the Society for Hematopathology and the European Association for Haematopathology highlighted various T-ALL/LBL genetic subtypes and showcased phenotypic diversity even among individuals with identical genetic abnormalities.</p><p><strong>Results: </strong>The data underscored the presence of significant genetic heterogeneity in T-ALL/LBL, highlighting the diagnostic value of specific genomic features for accurate classification, differentiation between immature and mature T-lymphoid neoplasms, and detection of underlying germline predisposition disorders. Further, the range of available standard molecular testing methodologies, including ancillary immunohistochemical studies, was discussed.</p><p><strong>Conclusions: </strong>A comprehensive standardized testing of genomic abnormalities will advance T-ALL/LBL characterization in future classification systems, as underscored by the cases submitted to Session 8 of SH2023. The genetic heterogeneity underscores the need for personalized therapies that target driver genomic abnormalities.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"76-84"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}